Recombinant Human Cadherin-17 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human Cadherin-17 protein (rFc Tag) (Eg2889)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2889

---

Validation Data Gallery

• 

  Purity of Recombinant Human Cadherin-17 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human Cadherin-17 protein Gln23-Met787 (Accession# Q12864) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 1015
• Accession: Q12864
• PredictedSize: 111.0 kDa
• SDS-PAGE: 110-140 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Cadherin-17 (CDH17), also known as Liver-Intestine cadherin (LI-cadherin), is a member of the cadherin superfamily. Cadherin-17 is expressed in various tissues, including the intestine and liver, and plays a role in cell adhesion, proliferation, and migration in colorectal cancer (CRC) metastasis. It binds and activates α2β1 integrin, promoting cell adhesion and proliferation. High expression of Cadherin-17 is significantly associated with liver metastasis and poor survival in patients with colorectal cancer.

References:

1.Bartolomé RA. et al. (2024). J Exp Clin Cancer Res. 43(1):31.
2.Bartolomé RA. et al. (2014). Oncogene. 33(13):1658-1669.